REMARKS/ARGUMENTS

Claims 4, 6-10, 16, 19-22, 25, and 28 are pending in this application. Claims 12-15

and 17 were withdrawn from consideration, as drawn to non-elected matter and have been

cancelled.

Claims 9, 16 and 20 have been amended to define the antibody as a humanized

antibody as presented, in part, in previously presented claims 5 and 20.

No new matter is believed to have been added by this amendment.

Applicants reiterate their position that the claims are enabled and described, and

particularly for the humanized antibody claimed herein. Further, Applicants state that there is

insufficient evidence to demonstrate that the cited prior art inherently (i.e., each and every

time) achieve what is now claimed.

Reconsideration of the outstanding rejections in light of the amendments and remarks

contained herein is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Daniel J. Pereira

Registration No. 45,518

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 08/07)

4